ClinicalTrials.gg
Active, not recruitingNCT05091567IMforteUpdated Sep 9, 2026Results posted

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

A Phase 3 interventional study of Atezolizumab and Lurbinectedin in Small-Cell Lung Cancer, sponsored by Hoffmann-La Roche. Active, not recruiting at 93 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
660
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing PM 01183 in Small Cell Lung Carcinoma — 9 open to participants now, 11 under way, 3 of them phase 3. PM 01183 · Small Cell Lung Carcinoma.

Enrollment
3rd of 16
660 · median 69
Started
2021
the only one that year
Phase 3
5 of 16
2 open now
Primary completion
2024-07
later than 0 of 10 live
Registered
6th of 16
by date
Lead sponsor
1 of 16
Hoffmann-La Roche

Among the 16 studies testing PM 01183 in Small Cell Lung Carcinoma, this one is the 3rd largest by enrollment, is the only one that started in 2021, is one of 5 in phase 3, reaches primary completion later than 0 of the 10 other live ones, and was the 6th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

9 of the 16 studies testing PM 01183 in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About PM 01183

PM 01183: first FDA approval 2020 (ZEPZELCA), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing PM 01183 in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) after first-line induction therapy with carboplatin, etoposide, and atezolizumab. The study consists of 2 phases: an induction phase and a maintenance phase. Participants need to have an ongoing response or stable disease per the Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 criteria after completion of 4 cycles of carboplatin, etoposide, and atezolizumab induction treatment in order to be considered for eligibility screening for the maintenance phase. Eligible participants will be randomized in a 1:1 ratio to receive either lurbinectedin plus atezolizumab or atezolizumab in the maintenance phase.

03

Conditions studied

  • Small-Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for the Induction Phase:

  • PS of 0 or 1
  • No prior systemic therapy for ES-SCLC
  • Treatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLC
  • or cytologically confirmed ES-SCLC
  • Adequate hematologic and end-organ function to receive 4 cycles of induction treatment with carboplatin, etoposide and atezolizumab
  • , as defined by v1.1
  • Negative test and no evidence of active or at screening

Exclusion Criteria for the Induction Phase:

  • Presence or history of
  • Active or history of disease or deficiency
  • History of other than SCLC within 5 years prior to enrollment
  • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including , anti-PD-1, and anti-PD-L1 therapeutic antibodies, or lurbinectedin or trabectedin
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Treatment with therapy within 28 days prior to enrollment

Inclusion Criteria for the Maintenance Phase:

  • ECOG PS of 0 or 1
  • Ongoing response or stable disease per RECIST 1.1 after 4 cycles of induction therapy
  • Toxicities attributed to prior induction anti-cancer therapy or PCI resolved to Grade \<=1
  • Adequate hematologic and end-organ function

Exclusion Criteria for the Maintenance Phase:

  • Presence or history of CNS metastases
  • Receiving consolidative chest radiation
  • Severe infection within 2 weeks prior to randomization into the maintenance
  • Treatment with therapeutic oral or IV antibiotics at the time of randomization
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
660 participants (actual)

Study arms

  • Experimental
    Arm A: Atezolizumab+Lurbinectedin

    Induction phase: participants will receive standard of care atezolizumab on Day 1 of each 21-day cycle in combination with carboplatin on Day 1 and etoposide on Days 1, 2, and 3 of each 21-day cycle for 4 cycles. Maintenance phase: participants will receive atezolizumab on Day 1 of each 21-day cycle in combination with lurbinectedin on Day 1 of each 21-day cycle.

    Drug: Atezolizumab · Drug: Lurbinectedin · Drug: Carboplatin · Drug: Etoposide

  • Active comparator
    Arm B: Atezolizumab

    Induction phase: participants will receive standard of care atezolizumab on Day 1 of each 21-day cycle in combination with carboplatin on Day 1 and etoposide on Days 1, 2, and 3 of each 21-day cycle for 4 cycles. Maintenance phase: participants will receive atezolizumab on Day 1 of each 21-day cycle.

    Drug: Atezolizumab · Drug: Carboplatin · Drug: Etoposide

Interventions

  • Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 4 cycles in the induction phase. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle in the maintenance phase.

    Also known as: Tecentriq, RO5541267

  • Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 of each 21-day cycle in the maintenance phase.

    Also known as: PM01183/JZP712

  • Carboplatin will be administered according to the standard of care treatment for 4 cycles in the induction phase.

  • Etoposide will be administered according to the standard of care treatment for 4 cycles in the induction phase.

06

What researchers measure

Primary outcomes

  1. Randomized Phase: Independent Review Facility (IRF) - Assessed Progression Free Survival (PFS)

    PFS was defined as the time from randomization to the date of first documented PD as determined by the IRF according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or death, whichever occurs first. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimetres (mm).

    Time frame: Up to 26 months

  2. Randomized Phase: Overall Survival (OS)

    OS was defined as the time from randomization to the date of death from any cause.

    Time frame: Up to 26 months

Secondary outcomes

  1. Randomized Phase: Investigator-assessed PFS

    PFS was defined as the time from randomization to the date of first documented PD as assessed by investigator according to RECIST v1.1 or death, whichever occurs first. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Up to 26 months

  2. Randomized Phase: Confirmed Objective Response Rate (ORR) as Determined by the IRF

    ORR was defined as the percentage of participants with an objective tumor response of complete response (CR) or partial response (PR) as determined by the IRF using RECIST v.1.1. CR was defined as the disappearance of all target and non-target lesions or any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. Percentages have been rounded off.

    Time frame: Up to 26 months

  3. Randomized Phase: Confirmed ORR as Determined by the Investigator

    ORR was defined as the percentage of participants with an objective tumor response of CR or PR as determined by the investigator using RECIST v.1.1. CR was defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD.

    Time frame: Up to 26 months

  4. Randomized Phase: Duration of Response (DOR) as Determined by the IRF

    DOR was calculated for participants who had a best confirmed OR of CR/PR. DOR= time from first occurrence of a documented OR until the time of documented PD as determined by IRF assessment using RECIST v1.1 or death from any cause, whichever occurs first. CR=disappearance of all target and non-target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \<10 mm. PR= at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Up to 26 months

  5. Randomized Phase: DOR as Determined by the Investigator

    DOR was calculated for participants who had a best confirmed OR of CR/PR. DOR= time from first occurrence of a documented OR until the time of documented PD as determined by investigator using RECIST v1.1 or death from any cause, whichever occurs first. CR=disappearance of all target and non-target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \<10 mm. PR= at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Up to 26 months

  6. Randomized Phase: Percentage of Participants With PFS as Determined by the IRF at 6 Months and 12 Months

    PFS rate at 6 months and 12 months was defined as the percentage of participants who had not experienced PD as determined by the IRF according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Percentages have been rounded off.

    Time frame: Months 6 and 12

  7. Randomized Phase: Percentage of Participants With PFS Determined by Investigator at 6 Months and 12 Months

    PFS rate at 6 months and 12 months was defined as the percentage of participants who had not experienced PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Percentages have been rounded off.

    Time frame: Months 6 and 12

  8. Randomized Phase: Percentage of Participants With OS at 12 Months and 24 Months

    OS rate at 12 months and 24 months was defined as the percentage of participants who had not experienced death from any cause at 12 months and 24 months after randomization. Percentages have been rounded off.

    Time frame: Months 12 and 24

  9. Randomized Phase: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)

    An AE =any unfavorable \& unintended sign (including abnormal laboratory values/abnormal clinical test results), symptoms/disease temporally associated with the use of a pharmaceutical product, whether considered related to the pharmaceutical product. SAE=any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above. AESI= drug induced liver injury, suspected transmission of infectious agent via study treatment, hepatitis, systemic lupus erythematosus, hypersensitivity, etc. AESIs may include events not specified in the protocol.

    Time frame: Up to 26 months

  10. Randomized Phase: Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab

    For determining post-baseline incidence, participants were considered to be ADA-positive if they were ADA-negative or had missing data at baseline but developed at least one positive post-baseline ADA result during the randomized phase, or if they were ADA-positive at baseline and the titer of 1 or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the baseline titer result.

    Time frame: Up to 26 months

  11. Randomized Phase: Time to Confirmed Deterioration (TTCD) in Physical Functioning (PF) and Global Health Status (GHS) as Measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQC30)

    EORTC QLQ-C30=30 questions assessing 5 aspects of participant functioning(physical,emotional,role,cognitive \&social),3 symptom scales,GHS/QoL \& 6 single items.PF scale=5 questions about participants PF \& daily activities(strenuous activities,long walks,short walks,bed/chair rest \& needing help with eating,dressing,washing themselves/using the toilet).PF scale scored on 4-point scale(1=Not at All-4=Very Much).GHS/QoL scored on 7-point scale(1=Very Poor- 7=Excellent).Scores were linearly transformed to a range of 0-100,higher scores=higher response level \& better QoL.TTCD for PF \& GHS/QoL=time from the date of randomization until first confirmed clinically meaningful deterioration,which is decrease from baseline in PF/GHS score that must be held for at least 2 consecutive assessments/initial decrease above baseline followed by death attributable to cancer progression within 6 weeks of the last deteriorated assessment.Score change≥10-point change in subscale score,considered meaningful.

    Time frame: Up to 26 months

07

Results

Posted Dec 29, 2025

Participant flow

A total of 660 participants with ES SCLC took part in the study across 96 investigative sites in 13 countries.

Enrollment Phase
Participant flow — Enrollment Phase
MilestoneAtezolizumab + Carboplatin + EtoposideAtezolizumabAtezolizumab+ Lurbinectedin
Started66000
Enrolled safety analysis set (sas)65300
Completed57100
Not completed8900
Withdrew: Death3700
Withdrew: Adverse event2100
Withdrew: Progressive disease1000
Withdrew: Withdrawal by subject800
Withdrew: Symptomatic deterioration700
Withdrew: Physician decision300
Withdrew: Protocol violation200
Withdrew: Reason not specified100
Randomized Phase
Participant flow — Randomized Phase
MilestoneAtezolizumab + Carboplatin + EtoposideAtezolizumabAtezolizumab+ Lurbinectedin
Started0241242
Sas0240242
Completed000
Not completed0241242
Withdrew: Death0135112
Withdrew: Progressive disease020
Withdrew: Withdrawal by subject013
Withdrew: Lost to follow-up011
Withdrew: Ongoing in study0102126

Outcome measures

PrimaryRandomized Phase: Independent Review Facility (IRF) - Assessed Progression Free Survival (PFS)

PFS was defined as the time from randomization to the date of first documented PD as determined by the IRF according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or death, whichever occurs first. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimetres (mm).

Time frame:
Up to 26 months
Reported as:
Median · months
Randomized Phase: Independent Review Facility (IRF) - Assessed Progression Free Survival (PFS)
monthsAtezolizumabAtezolizumab+ Lurbinectedin
Randomized Phase: Independent Review Facility (IRF) - Assessed Progression Free Survival (PFS)2.14 ± 1.645.36 ± 4.24
Statistical analysis
  • Atezolizumab vs Atezolizumab+ Lurbinectedin · Log Rank · p = < .0001 · Hazard ratio (hr): 0.54 · 95% CI 0.43 to 0.67
PrimaryRandomized Phase: Overall Survival (OS)

OS was defined as the time from randomization to the date of death from any cause.

Time frame:
Up to 26 months
Reported as:
Median · months
Randomized Phase: Overall Survival (OS)
monthsAtezolizumabAtezolizumab+ Lurbinectedin
Randomized Phase: Overall Survival (OS)10.64 ± 9.4913.24 ± 11.89
Statistical analysis
  • Atezolizumab vs Atezolizumab+ Lurbinectedin · Log Rank · p = = 0.0174 · Hazard ratio (hr): 0.73 · 95% CI 0.57 to 0.95
SecondaryRandomized Phase: Investigator-assessed PFS

PFS was defined as the time from randomization to the date of first documented PD as assessed by investigator according to RECIST v1.1 or death, whichever occurs first. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Up to 26 months
Reported as:
Median · months
Randomized Phase: Investigator-assessed PFS
monthsAtezolizumabAtezolizumab+ Lurbinectedin
Randomized Phase: Investigator-assessed PFS2.73 ± 2.535.36 ± 4.30
Statistical analysis
  • Atezolizumab vs Atezolizumab+ Lurbinectedin · Hazard ratio (hr): 0.55 · 95% CI 0.45 to 0.68
SecondaryRandomized Phase: Confirmed Objective Response Rate (ORR) as Determined by the IRF

ORR was defined as the percentage of participants with an objective tumor response of complete response (CR) or partial response (PR) as determined by the IRF using RECIST v.1.1. CR was defined as the disappearance of all target and non-target lesions or any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. Percentages have been rounded off.

Time frame:
Up to 26 months
Reported as:
Number · percentage of participants
Randomized Phase: Confirmed Objective Response Rate (ORR) as Determined by the IRF
percentage of participantsAtezolizumabAtezolizumab+ Lurbinectedin
Randomized Phase: Confirmed Objective Response Rate (ORR) as Determined by the IRF10.4 ± 6.4019.4 ± 13.85
Statistical analysis
  • Atezolizumab vs Atezolizumab+ Lurbinectedin · Difference in overall response rates: 8.99 · 95% CI 1.07 to 16.90
SecondaryRandomized Phase: Confirmed ORR as Determined by the Investigator

ORR was defined as the percentage of participants with an objective tumor response of CR or PR as determined by the investigator using RECIST v.1.1. CR was defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD.

Time frame:
Up to 26 months
Reported as:
Number · percentage of participants
Randomized Phase: Confirmed ORR as Determined by the Investigator
percentage of participantsAtezolizumabAtezolizumab+ Lurbinectedin
Randomized Phase: Confirmed ORR as Determined by the Investigator13.2 ± 8.8617.1 ± 12.19
Statistical analysis
  • Atezolizumab vs Atezolizumab+ Lurbinectedin · Difference in overall response rates: 3.90 · 95% CI -3.51 to 11.32
SecondaryRandomized Phase: Duration of Response (DOR) as Determined by the IRF

DOR was calculated for participants who had a best confirmed OR of CR/PR. DOR= time from first occurrence of a documented OR until the time of documented PD as determined by IRF assessment using RECIST v1.1 or death from any cause, whichever occurs first. CR=disappearance of all target and non-target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \<10 mm. PR= at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Up to 26 months
Reported as:
Median · months
Randomized Phase: Duration of Response (DOR) as Determined by the IRF
monthsAtezolizumabAtezolizumab+ Lurbinectedin
Randomized Phase: Duration of Response (DOR) as Determined by the IRF5.62 (4.17 to NA)9.00 (5.52 to NA)
SecondaryRandomized Phase: DOR as Determined by the Investigator

DOR was calculated for participants who had a best confirmed OR of CR/PR. DOR= time from first occurrence of a documented OR until the time of documented PD as determined by investigator using RECIST v1.1 or death from any cause, whichever occurs first. CR=disappearance of all target and non-target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \<10 mm. PR= at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Up to 26 months
Reported as:
Median · months
Randomized Phase: DOR as Determined by the Investigator
monthsAtezolizumabAtezolizumab+ Lurbinectedin
Randomized Phase: DOR as Determined by the Investigator11.93 (8.38 to NA)5.75 (4.17 to 11.10)
SecondaryRandomized Phase: Percentage of Participants With PFS as Determined by the IRF at 6 Months and 12 Months

PFS rate at 6 months and 12 months was defined as the percentage of participants who had not experienced PD as determined by the IRF according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Percentages have been rounded off.

Time frame:
Months 6 and 12
Reported as:
Number · percentage of participants
Randomized Phase: Percentage of Participants With PFS as Determined by the IRF at 6 Months and 12 Months
percentage of participantsAtezolizumabAtezolizumab+ Lurbinectedin
6 Months18.66 ± 13.4541.22 ± 34.58
12 Months12.03 ± 7.2720.54 ± 14.37
Statistical analysis
  • Atezolizumab vs Atezolizumab+ Lurbinectedin · Difference in event free rate: 22.56 · 95% CI 14.12 to 31.00
  • Atezolizumab vs Atezolizumab+ Lurbinectedin · Difference in event free rate: 8.51 · 95% CI 0.72 to 16.31
SecondaryRandomized Phase: Percentage of Participants With PFS Determined by Investigator at 6 Months and 12 Months

PFS rate at 6 months and 12 months was defined as the percentage of participants who had not experienced PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Percentages have been rounded off.

Time frame:
Months 6 and 12
Reported as:
Number · percentage of participants
Randomized Phase: Percentage of Participants With PFS Determined by Investigator at 6 Months and 12 Months
percentage of participantsAtezolizumabAtezolizumab+ Lurbinectedin
6 Months22.56 ± 17.1246.21 ± 39.60
12 Months12.80 ± 8.0720.32 ± 14.33
Statistical analysis
  • Atezolizumab vs Atezolizumab+ Lurbinectedin · Difference in event free rate: 23.65 · 95% CI 15.09 to 32.20
  • Atezolizumab vs Atezolizumab+ Lurbinectedin · Difference in event free rate: 7.53 · 95% CI -0.11 to 15.16
SecondaryRandomized Phase: Percentage of Participants With OS at 12 Months and 24 Months

OS rate at 12 months and 24 months was defined as the percentage of participants who had not experienced death from any cause at 12 months and 24 months after randomization. Percentages have been rounded off.

Time frame:
Months 12 and 24

Results for this outcome have not been posted.

SecondaryRandomized Phase: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)

An AE =any unfavorable \& unintended sign (including abnormal laboratory values/abnormal clinical test results), symptoms/disease temporally associated with the use of a pharmaceutical product, whether considered related to the pharmaceutical product. SAE=any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above. AESI= drug induced liver injury, suspected transmission of infectious agent via study treatment, hepatitis, systemic lupus erythematosus, hypersensitivity, etc. AESIs may include events not specified in the protocol.

Time frame:
Up to 26 months
Reported as:
Count of participants · Participants
Randomized Phase: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)
ParticipantsAtezolizumabAtezolizumab+ Lurbinectedin
AEs194235
SAEs4175
AESIs for Atezolizumab5476
AESIs for Lurbinectedin6293
SecondaryRandomized Phase: Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab

For determining post-baseline incidence, participants were considered to be ADA-positive if they were ADA-negative or had missing data at baseline but developed at least one positive post-baseline ADA result during the randomized phase, or if they were ADA-positive at baseline and the titer of 1 or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the baseline titer result.

Time frame:
Up to 26 months
Reported as:
Count of participants · Participants
Randomized Phase: Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
ParticipantsAtezolizumabAtezolizumab+ Lurbinectedin
Randomized Phase: Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab2019
SecondaryRandomized Phase: Time to Confirmed Deterioration (TTCD) in Physical Functioning (PF) and Global Health Status (GHS) as Measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQC30)

EORTC QLQ-C30=30 questions assessing 5 aspects of participant functioning(physical,emotional,role,cognitive \&social),3 symptom scales,GHS/QoL \& 6 single items.PF scale=5 questions about participants PF \& daily activities(strenuous activities,long walks,short walks,bed/chair rest \& needing help with eating,dressing,washing themselves/using the toilet).PF scale scored on 4-point scale(1=Not at All-4=Very Much).GHS/QoL scored on 7-point scale(1=Very Poor- 7=Excellent).Scores were linearly transformed to a range of 0-100,higher scores=higher response level \& better QoL.TTCD for PF \& GHS/QoL=time from the date of randomization until first confirmed clinically meaningful deterioration,which is decrease from baseline in PF/GHS score that must be held for at least 2 consecutive assessments/initial decrease above baseline followed by death attributable to cancer progression within 6 weeks of the last deteriorated assessment.Score change≥10-point change in subscale score,considered meaningful.

Time frame:
Up to 26 months
Reported as:
Median · months
Randomized Phase: Time to Confirmed Deterioration (TTCD) in Physical Functioning (PF) and Global Health Status (GHS) as Measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQC30)
monthsAtezolizumabAtezolizumab+ Lurbinectedin
TTCD for PFNA (NA to NA)15.9 (11.0 to NA)
TTCD for GHS/QoL12.9 (11.6 to NA)10.8 (7.6 to NA)

Adverse events

Collected over Enrollment Phase: Up to 6 months Randomization Phase: up to 26 months Study is ongoing & data up to primary clinical cut-off date is reported. Final data to be reported 1 year after study completion.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atezolizumab + Carboplatin + Etoposide54/660 (8.2%)181/653 (27.7%)526/653 (80.6%)
Atezolizumab135/241 (56%)41/240 (17.1%)127/240 (52.9%)
Atezolizumab+ Lurbinectedin113/242 (46.7%)75/242 (31%)213/242 (88%)
Most frequent serious events
Showing 10 of 169
Most frequent serious events
EventAtezolizumab + Carboplatin + EtoposideAtezolizumabAtezolizumab+ Lurbinectedin
AnaemiaBlood and lymphatic system disorders25/6530/2402/242
PneumoniaInfections and infestations22/6536/2406/242
Febrile neutropeniaBlood and lymphatic system disorders22/6530/2404/242
Respiratory tract infectionInfections and infestations3/6531/2405/242
Platelet count decreasedInvestigations4/6530/2405/242
DyspnoeaRespiratory, thoracic and mediastinal disorders2/6534/2405/242
HyponatraemiaMetabolism and nutrition disorders12/6533/2402/242
SepsisInfections and infestations11/6531/2401/242
InfectionInfections and infestations0/6530/2403/242
Myocardial infarctionCardiac disorders2/6530/2403/242
Most frequent other events
Showing 10 of 27
Most frequent other events
EventAtezolizumab + Carboplatin + EtoposideAtezolizumabAtezolizumab+ Lurbinectedin
AnaemiaBlood and lymphatic system disorders268/65316/24075/242
NauseaGastrointestinal disorders114/6539/24086/242
FatigueGeneral disorders76/65319/24048/242
Decreased appetiteMetabolism and nutrition disorders67/65316/24041/242
NeutropeniaBlood and lymphatic system disorders110/6534/24026/242
AlopeciaSkin and subcutaneous tissue disorders108/6532/2401/242
Neutrophil count decreasedInvestigations102/6533/24031/242
Platelet count decreasedInvestigations49/6537/24035/242
DiarrhoeaGastrointestinal disorders55/65318/24034/242
ConstipationGastrointestinal disorders90/65313/24027/242

Baseline characteristics

Full Analysis Set (FAS) included all participants randomized into the randomized phase, regardless of whether or not the assigned study treatment was received. Analysis was performed on the randomized treatment arms.

Age, Continuous
Age, Continuous(years)AtezolizumabAtezolizumab+ LurbinectedinTotal
Mean66.0 ± 8.065.1 ± 7.665.5 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)AtezolizumabAtezolizumab+ LurbinectedinTotal
Female9091181
Male151151302
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AtezolizumabAtezolizumab+ LurbinectedinTotal
Hispanic or Latino161632
Not Hispanic or Latino210206416
Unknown or Not Reported152035
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AtezolizumabAtezolizumab+ LurbinectedinTotal
American Indian or Alaska Native011
Asian313162
Native Hawaiian or Other Pacific Islander000
Black or African American134
White199195394
More than one race000
Unknown or Not Reported101222
08

Study locations

93 sites
09

References and documents

Publications

  • Paz-Ares L, Borghaei H, Liu SV, Peters S, Herbst RS, Stencel K, Majem M, Sendur MAN, Czyzewicz G, Caro RB, Lee KH, Johnson ML, Karadurmus N, Grohe C, Baka S, Csoszi T, Ahn JS, Califano R, Yang TY, Kemal Y, Ballinger M, Cuchelkar V, Graupner V, Lin YC, Chakrabarti D, Bhatt K, Cai G, Iannone R, Reck M; IMforte investigators. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2025 Jun 14;405(10495):2129-2143. doi: 10.1016/S0140-6736(25)01011-6. Epub 2025 Jun 2. PubMed 40473449 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Jul 2024, 32 months.

Results were first posted in Dec 2025, 1 year 5 months after primary completion.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's 32 months is close to that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2021
First posted
Oct 25, 2021
StartActual
Nov 18, 2021
Primary completionActual
Jul 29, 2024
CompletionEst.
Feb 28, 2028
Results first posted
Dec 29, 2025
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05091567
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 25, 2021
Start date
Nov 18, 2021
Primary completion
Jul 29, 2024
Completion
Feb 28, 2028 (estimated)
Results posted
Dec 29, 2025
Last update
Sep 9, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PM 01183

Start the discussion